By Denny Jacob

Bristol Myers Squibb on Thursday said commercial production at its cell therapy manufacturing facility received U.S. Food and Drug Administration approval.

The biopharmaceutical product developer said the Devens, Mass.-based facility is critical to its global cell therapy manufacturing footprint for long-term supply of the company's cell therapy portfolio.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

June 08, 2023 17:21 ET (21:21 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Bristol Myers Squibb Charts.